(Q39435697)

English

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

United States of America

0 references

pneumococcal conjugate vaccine

1 reference

based on heuristic

inferred from title

author name string

Ruth Link-Gelles

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Thomas Taylor

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Matthew R Moore

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Active Bacterial Core Surveillance Team

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

11 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

2572-2577

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Healthcare utilization and cost of pneumococcal disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Active bacterial core surveillance of the emerging infections program network

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Streptococcus pneumoniae serotype 19A in children, South Korea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Comparison of NIS and NHIS/NIPRCS vaccination coverage estimates. National Immunization Survey. National Health Interview Survey/National Immunization Provider Record Check Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Serotype replacement in disease after pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.049

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.03.049

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39435697&oldid=1477777984"